Avion Pharmaceuticals, LLC, a leading specialty pharmaceutical company, has reportedly announced that it has signed a new license and commercialization agreement with two wholly owned Aspen Pharmacare Holdings subsidiaries, namely Aspen Global Incorporated and Aspen Pharma USA Inc., to relaunch the Cenestin® tablet.
The Cenestin tablet is the first ever plant-based mix of nine conjugated estrogens substances specified for treatment of moderate-severe vulvar and vaginal atrophy symptoms and severe to moderate vasomotor symptoms caused by menopause. Cenestin® would be available in 1.25 mg, 0.9 mg, 0.625 mg, 0.45 mg, and 0.3 mg synthetic conjugated estrogens concentrations.
The symptoms of vasomotor are known to be prevalent in nearly 40-50 million women across the U.S. with around 1.3 million women entering menopause every year. Through the relaunch of Cenestin® tablets, menopausal women would have access to a plant-based option for conjugated estrogens products to treat vasomotor indications related to menopause. The result of two clinical studies deemed Cenestin® to be safe, effective, and a well-tolerated medicine.
Art Deas, Avion Pharmaceuticals CEO, stated that Cenestin® would let the firm expand its commitment towards women who are looking for options for managing their menopause journey and would allow for effectual symptom management.
Stephen Saad, Chief Executive of Aspen Group, stated that Avion’s experience and success in Women’s Health would provide an ideal partnership for relaunching Cenestin. The new agreement is a new step towards enhancing the firm’s presence in the U.S. by leveraging its niche global intellectual property.
About Avion Pharmaceuticals:
Avion Pharmaceuticals is leading pharmaceutical company, that develops, acquires, and markets a portfolio of new and innovative medicinal products in the Women's Health and other therapeutic groups, with its sole mission of enhancing the quality of patient lives.